TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04403802

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placebo Socks
Description: Placebo socks are identical to the Voxx Human Performance Technology socks but do not include the Voxx Human Performance Technology pattern woven into the sock. Placebo socks are made of the same fabric as Voxx Human Performance Technology socks and are drug and electrical free.~Prior to the 2-week treatment window, patients will be provided with 6 pairs of placebo socks. Patients will be asked to wear the socks continuously during both waking and sleeping hours, except when showering, bathing, or swimming.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placebo Socks
Description: Placebo socks are identical to the Voxx Human Performance Technology socks but do not include the Voxx Human Performance Technology pattern woven into the sock. Placebo socks are made of the same fabric as Voxx Human Performance Technology socks and are drug and electrical free.~Prior to the 2-week treatment window, patients will be provided with 6 pairs of placebo socks. Patients will be asked to wear the socks continuously during both waking and sleeping hours, except when showering, bathing, or swimming.
Study: NCT04363385

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Biological test
Description: Blood sample
Study: NCT01322438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib (BAY73-4506) + rifampin
Description: Drug: BAY73-4506 A single 160-mg dose of BAY73-4506 will be administered in the fasted state on Day 1 as four 40 mg tablets. Drug: BAY73-4506 and rifampin 600 mg once a day doses of rifampin will be orally administered after overnight fasting from Day 15 to Day 23. A single 160-mg dose of BAY73-4506 will be administered in the fasted state on Day 21 as four 40 mg tablets.
Study: NCT05498896

Intervention type: DRUG
Group type: OTHER
Intervention: Atezolizumab
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipatasertib
Description: Oral

Intervention type: DRUG
Group type: OTHER
Intervention: Paclitaxel
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: IV infusion

Intervention type: DRUG
Group type: OTHER
Intervention: Doxorubicin
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: IV infusion

Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: IV infusion
Study: NCT02307110

Intervention type: OTHER
Group type: OTHER
Intervention: cross-sectional observation
Description: cross-sectional opthalmic examination
Study: NCT01333085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Study: NCT02958618

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 30 group
Description: A limited sphincterotomy (EST) was performed prior to the EPBD.The length of the sphincterotomy incision was limited to a third of the size of the papilla. A CRE balloon (diameter 10, 12, 15, 18) was chosen according to the diameter of bile duct. The balloon was then gradually filled with diluted contrast medium under endoscopic and fluoroscopic guidance to observe the disappearance of the waist. Once the waist disappeared, the balloon remained inflated for 30 seconds. The stones were then retrieved by a basket or retrieval balloon. An ENBD catheter (.) was routinely placed into the CBD after stone removal.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 60 group
Description: A limited sphincterotomy (EST) was performed prior to the EPBD.The length of the sphincterotomy incision was limited to a third of the size of the papilla. A CRE balloon (diameter 10, 12, 15, 18) was chosen according to the diameter of bile duct. The balloon was then gradually filled with diluted contrast medium under endoscopic and fluoroscopic guidance to observe the disappearance of the waist. Once the waist disappeared, the balloon remained inflated for 60 seconds. The stones were then retrieved by a basket or retrieval balloon. An ENBD catheter (.) was routinely placed into the CBD after stone removal.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 180 group
Description: A limited sphincterotomy (EST) was performed prior to the EPBD.The length of the sphincterotomy incision was limited to a third of the size of the papilla. A CRE balloon (diameter 10, 12, 15, 18 ) was chosen according to the diameter of bile duct. The balloon was then gradually filled with diluted contrast medium under endoscopic and fluoroscopic guidance to observe the disappearance of the waist. Once the waist disappeared, the balloon remained inflated for 180 seconds. The stones were then retrieved by a basket or retrieval balloon. An ENBD catheter (.) was routinely placed into the CBD after stone removal.
Study: NCT02029040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3% Hypertonic Saline
Description: Within 5-15 minutes following the administration of the study drug, the Respiratory Distress Assessment Instrument (RDAI) score will be reassessed and study interventions are complete. The patient will be observed for one hour in the emergency department (ED). However, further treatments may be started immediately upon discretion of the treating physician. If the patient is discharged home study PI and/or research assistant will call the parents 7 days from the ED visit to check the number of visits to their primary doctor and/or EDs due to same illness.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9 % normal saline
Description: Within 5-15 minutes following the administration of the study drug, the Respiratory Distress Assessment Instrument (RDAI) score will be reassessed and study interventions are complete. The patient will be observed for one hour in the emergency department (ED). However, further treatments may be started immediately upon discretion of the treating physician. If the patient is discharged home study PI and/or research assistant will call the parents 7 days from the ED visit to check the number of visits to their primary doctor and/or EDs due to same illness.
Study: NCT04797819

Intervention type: DIAGNOSTIC_TEST
Intervention: Coronary plaque components
Description: Coronary plaque components were detected by CCTA method

Intervention type: DIAGNOSTIC_TEST
Intervention: Coronary plaque components
Description: Coronary plaque components were detected by CCTA method

Intervention type: DIAGNOSTIC_TEST
Intervention: Coronary plaque components
Description: Coronary plaque components were detected by CCTA method

Intervention type: DIAGNOSTIC_TEST
Intervention: Coronary plaque components
Description: Coronary plaque components were detected by CCTA method
Study: NCT01085565

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ExAblate 2100
Description: Conformal Bone System
Study: NCT02796287

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: achieving a neuropsychological examination in the acute amnesic phase
Description: achieving a neuropsychological examination in the acute phase in addition to the normal protocole
Study: NCT02971436

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Competitor's PAP Released Device + Pressure Support A
Description: Competitor's PAP Released Device + Pressure Support A

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Competitor's PAP Released Device + Pressure Support B
Description: Competitor's PAP Released Device + Pressure Support B
Study: NCT01608815

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Typhoid Vi polysaccharide
Description: 0.5 mL, Intramuscular
Study: NCT01506154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRX-7EAT
Description: Once daily application of a patch for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MRX-7EAT
Description: Once daily application of a patch for 14 days
Study: NCT02484651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: Reversal of deep neuromuscular block
Study: NCT02796287

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neurological consultation with neuropsychological evaluation
Description: Neurological consultation with neuropsychological evaluation one year after the acute amnesic phase

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MRI
Description: Brain MRI with the same protocol or an acquisition time of 15 minutes without gadolinium, one year after the acute amesic phase
Study: NCT01442272

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hidroferol®
Description: Hidroferol® drinkable ampoule in oral solution, 266 mcg (1 drinkable ampoule) each 15 days during 12 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paricalcitol: Zemplar®
Description: Paricalcitol (Zemplar®) oral capsule , 1 mcg (1 capsule)each 24 hours during 12 months

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Habitual medication
Description: Habitual medication
Study: NCT03593993

Intervention type: PROCEDURE
Intervention: Surgical Cohort
Description: Blood, cerebrospinal fluid, and surgical tissue collected during procedure
Study: NCT02179372

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid
Description: 30 subject with Crohn's Disease and/or Ulcerative Colitis in clinical remission but with fecal calprotectin value \>150 μg/g will recive 2 g/day of Eicosapentaenoic acid for 6 months treatment. At 3 months and 6 months, fecal calprotectin and clinical activity (CDAI for Crohn's Disease and SCCAI for Ulcerative Colitis) will be measured. The effect of Eicosapentaenoic acid on fecal calprotectin level will be monitored. Clinical relapses will be considered during the study.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Medium chain fatty acid (placebo)
Description: 30 subject with Crohn's Disease and/or Ulcerative Colitis in clinical remission but with fecal calprotectin value \>150 μg/g will recive 2 g/day of medium chain fatty acids for 6 months treatment. At 3 months and 6 months, fecal calprotectin and clinical activity (CDAI for Crohn's Disease and SCCAI for Ulcerative Colitis) will be measured.
Study: NCT01630590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Starting dose of 60 mg by mouth every day of a 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgen Ablation Therapy
Description: Androgen ablation therapy, either by means of luteinizing hormone-releasing hormone super-agonist (of any formulation), LHRH antagonist, or surgical castration given upon decision of study doctor.
Study: NCT04100460

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 7.25 grams of Arabinoxylan leaf fiber extract
Description: Participants are given 7.25 grams of Arabinoxylan daily

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 14.5 grams of Arabinoxylan leaf fiber extract
Description: Participants are given 14.5 grams of Arabinoxylan daily

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control - No Arabinoxylan
Description: Participants are given no Arabinoxylan
Study: NCT00325936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilnidipine
Description: 10\~20mg, qd, po for 3 months or 12 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cilnidipine
Description: 10\~20mg, qd, po for 3 months or 12 months.
Study: NCT01606956

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The cuff inflation by the resting volume
Description: 80 patients are randomly allocated into two groups : resting volume group (n=40), half the maximum volume group (n=40). In the resting volume group, the pilot balloon valve is connected to syringe without piston for keeping the valve open to the atmosphere and allowing the pressure within the cuff of LMA to equalize with atmospheric pressure. In the half the maximum volume group, the cuff of LMA is completely emptied and then the cuff is filled with the half the maximum volume.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: The cuff inflation by half the maximum volume
Description: 80 patients are randomly allocated into two groups : resting volume group (n=40), half the maximum volume group (n=40). In the resting volume group, the pilot balloon valve is connected to syringe without piston for keeping the valve open to the atmosphere and allowing the pressure within the cuff of LMA to equalize with atmospheric pressure. In the half the maximum volume group, the cuff of LMA is completely emptied and then the cuff is filled with the half the maximum volume.
Study: NCT03487718

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Leukocyte platelet rich fibrin plug + d-PTFE membrane
Description: Following tooth extraction, an autologous leukocyte platelet rich fibrin plug will be placed in the socket and covered with a d-PTFE membrane

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: d-PTFE membrane
Description: Following tooth extraction, the socket will be covered with a d-PTFE membrane
Study: NCT00846833

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Haploidentical NK cell
Description: 1. Collection of PBMCs by leukapheresis~2. CD3+ depletion of apheresis product using CliniMACS®
Study: NCT03648593

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: work recovery intervention
Description: Recover! app: one hour weekly for two months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: waiting list control
Description: no treatment during 6 months,then Recover! app
Study: NCT03422458

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alveolar Ridge Preservation
Description: Insertion of a bone substitute material (BioOss Collagen) within the bony envelope at least to the level of the palatal/ lingual bone plate. Adaptation of a collagen matrix (Mucograft Seal) to the soft tissue borders.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alveolar Ridge Preservation
Description: Insertion of a bone substitute material (BioOss Collagen) within the bony envelope at least to the level of the palatal/ lingual bone plate. Adaptation of a collagen matrix (Mucograft Seal) to the soft tissue borders.
Study: NCT02351882

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nabilone
Description: Participants randomized to nabilone treatment arm, will undergo a one-week placebo washout, followed by 6 weeks of nabilone treatment (weeks 1-6). Participants will then receive a one-week placebo washout (week 7), before receiving 6 weeks of placebo treatment (weeks 8-14).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants randomized to placebo arm, will undergo a one-week placebo washout, followed by 6 weeks of drug matched placebo (weeks 1-6). Participants will then receive a one-week placebo washout (week 7), before receiving 6 weeks of nabilone treatment (weeks 8-14).
Study: NCT02684903

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Child Interaction Therapy
Description: PCIT is a 16-20 session live-coaching parenting intervention. PCIT for Child Welfare families is delivered in two sequential treatment phases following a motivational enhancement training: Phase 1, Child-Directed Interaction (CDI) to enhance positive parenting and interrupt harsh aversive parenting, and Phase 2, Parent-Directed Interaction (PDI) to coach effective parent commands and a consistent time-out protocol when child disobeys.
Study: NCT02424552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Initial single dose 100000 IU, beginning from the second day 4000 IU/day for 24 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Filling material: lactose monohydrate, cellulose, magnesium stearate
Study: NCT02484651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium
Description: Maintenance of deep neuromuscular block
Study: NCT02461524

Intervention type: DEVICE
Group type: OTHER
Intervention: Endurant Evo AAA Stent Graft System
Study: NCT01598428

Intervention type: PROCEDURE
Group type: OTHER
Intervention: anterior capsule polishing
Description: polish the anterior capsule and the equator of capsule extensively with a Whitman Shepherd Double-Ended Capsule Polisher
Study: NCT01421485

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated treatment program
Description: CBT, psychopharmacological treatment, family treatment, HIV prevention, case management

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Treatment in community, case management
Study: NCT02465021

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: All arms are given to all participants, in a randomized order

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: All arms are given to all participants, in a randomized order

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: All arms are given to all participants, in a randomized order

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: All arms are given to all participants, in a randomized order

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: All arms are given to all participants, in a randomized order

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: All arms are given to all participants, in a randomized order
Study: NCT02512510

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TD-4208

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TD-4208

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT05240274

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: metformin 500mg OD for 3 months to start within 10 days post-renal transplant

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo 500mg OD for 3 months to start within 10 days post-renal transplant
Study: NCT02109796

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial Direct current stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial Direct current stimulation
Study: NCT02491892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Participants will receive one of two IV treatment regimens with pertuzumab: either 420 mg every 3 weeks, with an initial 840-mg loading dose, or 1050 mg every 3 weeks with no loading dose administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Participants will receive one of two IV treatment regimens with pertuzumab: either 420 mg every 3 weeks, with an initial 840-mg loading dose, or 1050 mg every 3 weeks with no loading dose administered.
Study: NCT01682564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candemore tablet
Description: * Initial dose : 4mg/day if SBP\<140mmHg and/or DBP\<90mmHg, 8mg/day if SBP≥140mmHg and DBP≥90mmHg~* dose escalation : double dose if SBP≥100mmHg and DBP\>60mmHg (maximum dose 16mg/day)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atacand tablet
Description: * Initial dose : 4mg/day if SBP\<140mmHg and/or DBP\<90mmHg, 8mg/day if SBP≥140mmHg and DBP≥90mmHg~* dose escalation : double dose if SBP≥100mmHg and DBP\>60mmHg (maximum dose 16mg/day)
Study: NCT03713372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-EGFR monoclonal antibody
Description: Initially, 6.0mg/kg of SCT200 will be administered once a week for a maximum of 6 cycles. After 6 cycles, 8.0mg/kg of SCT200 will be administered every two weeks until disease progression.
Study: NCT05136911

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SALT-Intervention
Description: Participants in the intervention group will have access to all standard care as provided to the usual care group participants. In addition, participants in the intervention group will receive the SALT-intervention developed by the principal investigator in the form of a SALT-intervention consist of the Salt Intervention manual, five online modules which include a virtual cooking demonstration and five ten-minute weekly telephone calls delivered by the principal investigator.These strategies aim to increase knowledge, enhance self-management abilities and provide social support.
Study: NCT03418935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remaxol (succinate + methionine + inosine + nicotinamide)
Description: Solution for intravenous infusions, containing succinate, methionine, inosine, and nicotinamide in 400 ml glass bottle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remaxol (succinate + methionine + inosine + nicotinamide)
Description: Solution for intravenous infusions, containing succinate, methionine, inosine, and nicotinamide in 400 ml glass bottle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ringer's Solution
Description: Intravenous infusion, 400 or 800 ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ringer's Solution
Description: Intravenous infusion, 400 or 800 ml
Study: NCT01952964

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: JUC spray dressing
Description: Intervention group Care of Tenckhoff catheter exit site using spray dressing. The detailed procedures will be introduced by the nurse according to the protocol of the unit. Please refer to Appendix III for details.~Skin test with JUC spray will be carried out prior to the usage of JUC spray dressing for caring the exit site. For the first three days after patient has been discharged, study team members will perform telephone follow up. Patients are reminded to report for signs and symptoms of infection or physical damage of catheter noted. A routine follow up at the Renal Unit will be arranged at eight weeks intervals.
Study: NCT01812005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alisertib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alisertib
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Laboratory correlative studies will be performed

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Laboratory correlative studies will be performed
Study: NCT03508804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine-Prilocaine Cream
Description: 10ml of vaginally self-administered cream composed of an eutectic mixture of 2.5% lidocaine, 2.5% prilocaine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Cream
Description: 10ml of vaginally self-administered placebo cream